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Highlights 
 There is a lack of clarity around the relationship between oxidative stress and frailty. 
 Our review provides some cross sectional evidence of increased oxidative stress among frail 
older people. 
 There is some preliminary evidence of lower anti-oxidant parameters (vitamin C, E, α-
tocopherol, biological anti-oxidant potential, total thiol levels) in frailty.   
 
 
ABSTRACT (250/250) 
Objective: Oxidative stress (OS) is associated with accelerated aging. Previous studies have 
suggested a possible relationship between OS and frailty but this association remains unclear. 
We conducted a systematic review to investigate potential interactions between OS and 
frailty. 
Methods: A systematic literature search of original reports providing data on ‘OS and 
antioxidant’ parameters and frailty was carried out across major electronic databases from 
inception until May 2016. Cross-sectional/case control and longitudinal studies reporting data 
on the association between frailty and anti-oxidants-OS biomarkers were considered for 
inclusion. Results were summarized with a best-evidence based synthesis.  
Results: From 1,856 hits, 8 studies (cross-sectional/case control) were included (N=6,349; 
mean age of 75±12 years; 56.4% females). Overall, there were 588 (=9.3%) frail, 3,036 pre-
frail (=47.8%), 40 (=0.6%) pre-frail/robust, and 2,685 (=42.3%) robust subjects. Six cross-
sectional/case control studies demonstrated that frailty was associated with an increase in 
peripheral OS biomarkers including lipoprotein phospholipase A2 (studies=1), isoprostanes 
(studies=2), Malonaldehyde (studies=2), 8-hydroxy-20-deoxyguanosine (studies=2), derivate 
of reactive oxygen metabolites (studies=2), oxidized Glutathione/ Glutathione (studies=1), 4-
hydroxy-2,3-nonenal (studies=1), and protein carbonylation levels (study=1). In addition, 
preliminary evidence points to lower anti-oxidant parameters (vitamin C, E, α-tocopherol, 
biological anti-oxidant potential, total thiol levels) in frailty.   
Conclusion: Frailty and pre-frailty appear to be associated with higher OS and possibly lower 
anti-oxidant parameters. However, due to the cross sectional design, it is not possible to 
disentangle the directionality of the relationships observed.  Thus, future high quality and in 
particular longitudinal research is required to confirm/refute these relationships and to further 
elucidate pathophysiological mechanisms. 
 
INTRODUCTION 
Whılst the trajectory of aging can differ among older people (1), there is general agreement 
that aging is associated with an accumulation of cellular damage (2). The pathophysiological 
changes associated with aging can lead to mitochondrial dysfunction, failure of tissue repair 
mechanisms, accelerated cellular senescence, in addition to a reduction in tissue homeostasis, 
which may increase the risk of organ failure and mortality (3).  One of the most important 
factors that may increase cellular aging is oxidative stress (OS) (4).  During the aging process 
the balance between the cellular antioxidant defence system and toxic effects due to OS may 
deteriorate (5). Studies have reported that reactive oxygen species (ROS) could play a pivotal 
role in aging, and also in several age-related diseases such as sarcopenia, cerebrovascular, and 
neurodegenerative diseases (5).  
In recent years, an accumulating body of evidence has suggested that OS and inflammatory 
changes might play a role in the development of frailty, which is another common age-related 
clinical syndrome (6,7). Frailty is defined as “a state of increased vulnerability to stressors 
that results from decreased physiologic reserve in multiple organ systems causing limited 
capacity to maintain homeostasis” (8).  Frailty is associated with several deleterious 
outcomes, including a higher rate of hospitalization, depression, falls, disability and mortality 
in older adults (9). The main features of frailty traditionally include low physical activity 
levels, slowness in motor performance, and weakness, which may occur due to a loss of 
skeletal muscle mass and functioning (8-10). Furthermore, OS might lead to an activation of 
apoptotic pathways leading to cellular damage, aberrations in the expression of many 
transcription factors responsible for shifting protein synthesis to protein degradation, a decline 
in mitochondrial function, and an impairment of repair mechanisms (2, 11). These interacting 
pathways may contribute to the detrimental effects of OS on muscles, bones, and the immune 
system (12). Loss of muscle mass and strength may reduce physical activity and thereby 
contribute to frailty (13).  
A number of previous individual studies have suggested a possible relationship between OS 
and frailty (14,15), but this relationship remains unclear. Therefore, we conducted a 
systematic review to determine the potential association between OS biomarkers and frailty. 
Our priori hypothesis was that frailty could be associated with higher peripheral levels of 
reactive oxygen species biomarkers and with lower levels of antioxidants, resulting in 
increased OS. 
 
MATERIALS AND METHODS 
This systematic review was conducted following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) (16). An a priori unpublished protocol was followed 
(17).  
Search Strategy 
Two investigators (PS, BS) independently conducted an electronic literature search using 
EMBASE, PubMed and Scopus with no language restrictions.  The databases were searched 
from inception until 05/01/2016 for studies investigating the relationship between OS and 
frailty. Any inconsistencies were resolved by consensus with a third author (NV).  The search 
terms used in Pubmed were (frailty OR frail) AND (oxidative stress OR oxidative injury OR 
oxidative damage OR anti-oxidants OR Reactive oxygen species OR Free radical OR redox 
balance). Conference abstracts were also considered. 
Study selection 
Included studies were those that (1) reported on peripheral levels of OS related biomarkers 
(reactive oxygen species related and  anti-oxidants parameters) as a function of frailty status; 
(2) used a validated and standardized method for assessing frailty (e.g. those suggested by 
Fried et al.) (18); and (3) included a control group (pre-frail and robust as separate entities or 
together). Studies were excluded if they (1) did not use clear diagnostic criteria for frailty or 
used only one item for its diagnosis (e.g. low gait speed), (2) animal or in vitro research, (3) 
case reports, (4) did not measure or did not report serum OS biomarkers levels or anti-oxidant 
parameters. 
 
 
Data extraction 
Two authors (BS, PS) independently extracted data from the selected studies in a standardized 
Microsoft Excel spreadsheet. Any disagreement was resolved through discussion with a third 
author (NV). The following information was extracted: i) characteristics of the study 
population (e.g. sample size, demographics, country in which the study was performed); ii) 
setting in which the study was performed; iii) diagnostic criteria for frailty; iv) OS parameters 
assessed with corresponding assays; v) demographic characteristics (mean age and percentage 
of women) and mean body mass index (BMI) according to frailty status.  
 
Methodological quality assessment 
Study quality was assessed by two investigators (PS, BS), whilst a third reviewer was 
available for mediation (NV).  For cross-sectional studies, the Newcastle-Ottawa Scale (NOS) 
was used to assess study quality. The NOS assigns a maximum of 9 points based on three 
quality parameters: selection, comparability, and outcome (19).  
 
Statistical Analysis 
Due to the paucity and heterogeneity in outcomes and study samples, the findings of this 
review are summarized in a best evidence synthesis.   
 
RESULTS 
The search identified 1250 potentially eligible studies. After excluding 1221 manuscripts 
through title/abstract screening, 29 full-text articles were examined and 8 studies (14,15,20-
25) were included in this systematic review (Figure 1).   
 
Study and Participant Characteristics  
Studies and participant characteristics are summarized in Table 1. The 8 studies (14,15,20-25) 
included a total of 6,349 participants with a mean age of 75±12 years and mainly women 
(=56.4%). Overall, there were 588 (=9.3%) frail, 3,036 pre-frail (=47.8%) and 2,685 
(=42.3%) robust, and 40 (=0.6%) pre-frail/robust subjects. All included studies were a cross-
sectional/case-control design. 
All included studies defined frailty using a modified version of Fried et al. (18) except for one 
study (22) in which the Rothman criteria (26) was used as a definition of frailty. 
The majority of the studies was conducted among community-dwelling older adults (4 
studies; =57.1%) and in Europe (n=4), followed by Asia (n=2) and America (n=2) (Table 1). 
The quality of the studies, assessed through NOS, was generally good with a median score of 
7 (range: 6-9) (Supplementary Table 1).  
Frail participants were older (76.7 ± 9.8 years), more frequently females (=61.7%) and 
exhibited higher BMI (=28.8 ± 6.7 kg/m2) than pre-frail (73.1 ± 9.1 years; % of females: 
56.6; BMI: 27.3 ± 7.3 kg/m2) and robust (68.9 ± 7.8 years; % of females: 49.2; BMI: 26.5 ± 
8.1 kg/m2) elders (Table 1). 
 
Association Between OS Biomarkers And Frailty 
As shown in Table 2, seven studies (14,15,21,22-25) reported data for peripheral OS 
biomarkers. Only one study did not find any significant difference between frail and robust 
groups regarding paraoxonase-1 (PON-1) and Malonaldehyde (MDA) levels (p>0.05) (22), 
but another study found higher MDA levels among frail elders (p<0.01) (24). All included 
studies, except one (22), reported that higher OS biomarkers were significantly associated 
with frailty (14,15,21,23-25). Oxidative stress biomarkers assayed across studies included 
lipoprotein phospholipase A2 (LpPLA2), isoprostanes, MDA, 4-hydroxy-2,3-nonenal (HNE), 
8-hydroxy-20-deoxyguanosine, derivate of reactive oxygen metabolites (d-ROM), Oxidized 
Glutathione/ Glutathione (GSSG/GSH), and protein carbonylation levels (p<0.05). The 
derivate of reactive oxygen metabolites (d-ROM) was evaluated in two studies, d-ROM levels 
were higher in frail/prefrail compare the robust elderly groups (p<0.01) (14, 25). Furthermore, 
levels of isoprostanes were increased in both frail and pre-frail elders in other two studies 
(p<0.05) (21,25). Finally, higher levels of 8-hydroxy-deoxyguanosine (8-OHdG), which were 
measured in urine in one and in blood in another study, were associated with frail/pre-frail 
status (p<0.05) (15,25) (Table 2).   
One study reported a statistically higher levels of OS among people with frailty versus people 
without frailty (p<0.01), but precise values are not reported in the paper (23).  
Association Between Anti-Oxidants Parameters and Frailty 
As shown in Table 3, four studies (14,20,22,25) reported data regarding anti-oxidant 
parameters. One study reported that levels of vitamin E decreased gradually from robust to 
frail subjects (p< 0.05) (20).  Another study did not find any significant difference between 
frail and pre-frail/ robust groups in α-tocopherol and vitamin C serum levels (22) (p>0.05). 
Two studies evaluated biological anti-oxidant potential (BAP) (14,25). One found that BAP 
levels were significantly lower in the frail participants compared to those who were pre-frail 
or robust (p< 0.05) (25).  However, another study did not find any statistical significant 
difference for BAP between those with frailty and people who were robust (p>0.05) (14). In 
one study, a significant association with frailty was observed for Total Thiol Levels (TTL) (p 
<0.0001) (14).  
DISCUSSION: 
In this systematic review, including eight studies and a total of 6,349 participants, we 
summarized the current evidence regarding the relationship between frailty and OS 
parameters.  Overall, available data suggest that in cross-sectional studies, there is evidence of 
higher levels of peripheral OS biomarkers and lower anti-oxidant parameters among frail 
older adults. One study did not find any such relationship and the reasons for may be due to 
the inclusion of pre-frail participants in the comparison group and that this study had a small 
sample size (22). 
 
Aging is influenced by multiple factors, including OS, inflammation, glycation, telomere 
shortening, mutations, degradation of proteins and enzymes, and a progressive damage of the 
structure and function of biomolecules, cells, and organs (27). The deteriorations related to 
OS rank first among causes of aging (4), and may lead to development of age-related diseases, 
such as macular degeneration, sarcopenia, cerebrovascular diseases, Alzheimer’s disease 
(AD), Parkinson’s disease, cancer, and consequently mortality (5,28), although the direction 
of this relationship is motive of debate. Furthermore, anti-oxidants have been proposed as 
novel therapeutic targets for several aging-associated diseases, due in part to their cardio-
protective, chemotherapeutic, and neuroprotective effects (29). Nowadays, effects of both OS 
and anti-oxidant parameters on the initiation and progression of age-related diseases remain 
unclear; however, clinical and experimental studies have intensively investigated this topic 
(4,5,27-29). 
 
In recent years it is thought that OS also may be associated with frailty, which develops 
slowly in a stepwise process, and may be precipitated by acute events (30), but the 
relationship between OS and frailty is complex since both linearly increase with advancing 
age. Both higher OS in the periphery and frailty are accompanied by several negative 
outcomes, such as higher mortality and multi-morbidity (9,28). Our systematic review 
suggests that frailty is associated with higher OS and lower anti-oxidant peripheral 
parameters. The relationship between OS and frailty could be explained by several 
hypotheses. First, OS may lead to musculoskeletal system damage due to the fact that OS 
increase intracellular calcium promoting proteasomal activity and accelerating muscle 
breakdown, and ROS may trigger the apoptosis of murine skeletal muscle, and decrease 
myoblast proliferation (12,31). These factors may contribute to a decline in muscle function 
and strength. Loss of muscle mass and strength can directly reduce physical activity levels. 
Low physical activity is one of the hallmarks of frailty (18), and has been consistently 
reported to significantly increase OS in both animal models and humans (13,32). Therefore, a 
vicious circle may occur between OS and frailty. Second, OS may also contribute to immune 
activation through generating oxidized cellular components (15). Frail people have a 
significant reduction in the function of the innate immune system, T-cell activity, the 
production of antibodies, and an increase in mitochondrial activity by means of OS products 
(7,33). In addition, predominantly inflammatory cytokines may influence frailty status either 
directly by promoting protein degradation, or indirectly by affecting important metabolic 
pathways (34). Third, frail and pre-frail participants have a higher prevalence of various 
medical disorders, including cardiovascular diseases, stroke, dementia and diabetes mellitus, 
all of which are both strongly associated with frailty and could also increase the generation of 
OS products (5,28). These chronic diseases, arising mainly in later life, may increase resting 
metabolic rate in order to maintain cellular homeostasis, which drive the generation of ROS 
by dysregulated mitochondria, ultimately leading to homeostatic deregulation and then loss of 
muscle strength (14). Finally, frail and pre-frail people are generally more obese than robust 
participants and obesity is highly associated with systemic OS (35). This hypothesis is also 
consistent with the fact that an increase in adiposity may affect muscle mass and walking 
ability among frail subjects (36). Clearly, future longitudinal work is required to disentangle 
the relationships we observed and elucidate potential pathophysiological mechanisms. 
 
Putative beneficial effects of antioxidants on frailty are not surprising when the 
aforementioned mechanisms are considered. Previous studies reported that there is a strong 
correlation of plasma concentrations of antioxidants and physical performance and strength 
among the elderly (37), and that the supplementation of antioxidants may improve muscle 
mass, grip strength, and mitochondrial dynamics in skeletal systems (38). Moreover, elderly 
people with lower peripheral antioxidant levels are more vulnerable to disability and mortality 
over a 5-year follow-up period (39). The findings of our systematic review may provide a 
further impetus to test antioxidants as novel treatment targets to prevent or manage frailty. 
 
Although this study has expanded the knowledge on this topic, it has a number of limitations, 
which are reflected by the available literature.  First, it should be kept noted that OS may 
increase exponentially during the aging process and since the data in the current study are 
cross sectional, no certainty can be made regarding the direction of the relationships observed.  
However, we attempted to try and disentangle the relationship of OS and frailty by stratifying 
the results according to frailty status (frail, pre frail and robust).  Another limitation is that due 
to the heterogeneity of the studies included, a meta-analysis could not be performed.  
Moreover, some potential confounders, such as medical comorbidities, and drugs, which may 
effect on frailty, could not be systematically considered. In addition, the relationdhip between 
OS and frailty may be bidirectional, thus neccessitating future longitudinal research to 
disentangle the directionality of the relationships observed.  Another limitation is that most 
studies defined frailty according to Fried et al. which focusses on physical frailty, and does 
not take into consideration other relevant features (e.g., cognitive frailty).  
 
In conclusion, our review suggest there is some suggestive evidence that frailty and pre-frailty 
are associated with higher peripheral OS and lower anti-oxidant parameters. However, future 
high-quality prospective research is warranted to confirm these findings.  
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Table 1. Descriptive findings of the studies included 
Author,year 
(Country) 
Setting 
 
Participants 
 
Mean age 
 
Mean 
BMI 
 
% 
Femal
e 
Diagnostic 
criteria for 
frailty 
OS parameters 
assessed 
Methods of 
measurement 
NOS 
Score 
Quality 
Ble, 2006 
(Italy) (20) 
 
Community 
Frail:54 
Pre-frail:313 
Robust:460 
 
NA 
 
NA 
 
NA 
 
Fried 
 
 
Plasma vitamin E 
 
High-performance 
liquid chromatography 
 
7 
 
Liu,2016 
(USA) (21) 
 
Community 
Frail:142 
Pre-frail:864 
Robust:913 
77±6 
72±7 
69± 6 
29.6 ± 7.0 
28.8 ± 5.3 
27.3 ± 4.5 
54 
57 
51 
 
Fried 
 
LpPLA2, 
isoprostanes 
 
ELISA 
 
9 
Goulet,2009 
(Canada)  
(22) 
Community 
and 
Inpatients 
Frail: 33 
Pre-frail/ 
Robust: 21 
 
82 ± 5 
79± 5 
 
27.8 ± 3.8 
27.1 ± 1.2 
73.0 
52.3 
 
Rothman 
criteria 
Malondialdehyde, 
Paraoxonase-1, 
antioxidant capacity 
(vitamin C, E) 
Spectrophotometer/ 
fluorimetric-liquid 
chromatographic 
 
7 
Serviddio, 
2009  (Italy) 
(23) 
 
 
Outpatients 
Frail:43 
 
Prefrail/Robus
t:19 
 
 
NA 
 
 
NA 
 
 
NA 
 
 
Fried 
Glutathione, 
Oxidized 
Glutathione, 
Malonaldehyde, 4-
hydroxy-2,3-nonenal 
 
Western Blot 
 
8 
Wu,2009 
(Taiwan)  
(15) 
Community 
and 
Outpatients 
Frail:21 
Pre-frail:56 
Robust:13 
79.9 ± 5.8 
76.8 ±5.8 
73.1 ±5.3 
 
NA 
 
NA 
 
Fried 
 
8-hydroxy-20-
deoxyguanosine 
 
ELISA 
 
6 
Saum, 
2015 
(Germany) 
(14) 
 
Community 
Frail:210 
Pre-frail:1463 
Robust:845 
73.7 ± 6.0 
70.3 ± 6.2 
67.8 ± 5.8 
30.2 ± 6.2 
28.7 ± 4.7 
28.3 ± 4.4 
64.8 
56.1 
43.4 
Fried derivate of reactive 
oxygen metabolites, 
biological anti-
oxidant potential, 
total thiol levels 
 
autoanalyzer 
 
9 
Ingle´s, 
2014 
(Spain) (24) 
 
Community 
Frail:51 
Pre-frail:278 
Robust:410 
78.8 ±6.0 
73.8 ±4.7 
72.4 ±4.2 
30.0 ±5.5 
29.5 ±4.9 
29.7 ± 5.0 
66.7 
57.5 
57.8 
 
Fried 
MDA and protein 
carbonylation 
High-Performance 
Liquid 
Chromatography, 
 
7 
Western 
Blotting 
Namioka, 
2016 
(Japan) 
(25) 
Outpatients Frail:34 
Pre-frail:62 
Robust:44 
82.3±6.1 
80.5±4.9 
78.2±6.0 
23.5 ±3.8 
22.3±3.1 
22.7±3.0 
67.6 
64.5 
43.1 
Fried Diacron reactive 
oxygen metabolite, 
8-Hydroxy-2 -
deoxyguanosine, 8-
isoprostane, 
biological anti-
oxidant potential 
ELISA, 
high-performance 
liquid chromatography 
 
 
9 
 
 
 
 
 
 
 
 
 
 
4: 
community-
dwelling; 2: 
Outpatients; 
1: both  
community-
dwelling 
and 
inpatients; 
2: both 
community 
and  
Outpatients 
 
 
Frail: 588 
Pre-frail: 
3036 
Robust: 2685 
Pre-
frail/robust:4
0 
 
Total: 6349 
 
Frail: 
76.7 ± 9.8 
Pre-frail: 
73.1 ± 9.1 
Robust: 
68.9 ± 7.8 
Pre-frail/ 
Robust: 
79± 5 
 
 
 
Frail: 
28.8 ± 6.7 
Pre-frail: 
27.3 ± 7.3 
Robust: 
26.5 ± 8.1 
Pre-frail/ 
Robust: 
27.1 ± 1.2 
 
 
61.7 
56.6 
49.2 
 
 
7: Fried's 
criteria 
1: 
Rothman 
   
 
Median
:7 
(6-9) 
 
BMI: Body Mass Index; ELISA: Enzyme-Linked Immuno Sorbent Assay;  LpPLA2: lipoprotein-associated phospholipase A2; MDA: Malonaldehyde; NA: 
Not applicable, NOS= Newcastle Ottawa Scale 
 
Table 2. Findings of the studies investigating oxidative biomarkers. 
Study Oxidative 
biomarkers 
Robust Pre-frail Frail 
Liu (21) LpPLA2 mass 
(ng/mL) 
 
199 (168,228)ꟸ 199 (172,229)ꟸ * 210 (183,237)ꟸ * 
 LpPLA2 activity 
(nm/mL/min) 
139 (119,166)ꟸ 137 (115,160)ꟸ * 139 (119,166)ꟸ * 
 Isoprostanes 
(mg/L) 
9.5 (7.1,12.8)ꟸ 10.2 
(7.60,14.30)ꟸ * 
11.5 
(8.50,15.40)ꟸ * 
Goulet  (22) PON-1 (µmol/L) 1.64 ± 1.04 
(robust+pre-frail) 
NA FL: 1.33 ± 1.01 
FO: 0.91 ± 0.91 
 MDA (µmol/L) 1.29 ± 0.41 
(robust+pre-frail) 
NA FL: 1.17 ± 0.36 
FO: 1.12 ± 0.31 
Wu (15) 8-hydroxy-20-
deoxyguanosine 
(mg/L) 
1.0 (0.5–5.3)~ 2.3 (0.5–8.1)~ 2.5 (1.5–6.2)~ * 
Saum (14) d-ROM (U.CARR) 339.6 (296.8 – 
385.4)~ 
354.8 (310.3 – 
398.3)~ 
371.6 (318.5 – 
420.5)~ ** 
Ingle´s (24) MDA (µM) 2.11 ±1.80 2.43 ±2.26 3.28 ±2.45* 
 Protein 
carbonylation 
levels (arbitrary 
units) 
64.36 ±14.29 
 
75.01± 15.51* 
 
 77.60 ±15.60* 
 
Namioka (25) Urine 8-OHdG 
(ng/mg Cre)  
3.90± 1.67  5.44±2.70** 5.39± 2.23** 
 8-isoprostane 
(pg/mg Cre) 
235± 98 305±126* 342± 175*** 
 Plasma dROM 
(U.CARR) 
418± 65 450±70* 485± 86*** 
 
ꟸmedian (25th percentile, 75th percentile)      ~median (range) 
*** for p-value <0.0001, ** for p<0.001 and * for p-value <0.05 compared with robust participants. 
d-ROM: derivate of reactive oxygen metabolites; FL: Frail Lean; FO: Frail obese; HNE: 4-hydroxy-2,3-
nonenal;  Isoprostanes: 8-epi-FGFα isoprostanes; LpPLA2: lipoprotein phospholipase A2; MDA: 
Malonaldehyde; NA: Not Applicable; PON-1: paraoxonase-1 
 
 
 
  
Table 3. Findings of the studies investigating anti-oxidants parameters. 
 
~ median (range) 
*** for p-value <0.0001, ** for p<0.001 and * for p-value <0.05 compared with robust;  
   BAP: Biological Anti-Oxidant Potential; FL: Frail Lean; FO: Frail obese; TTL: Total Thiol Levels 
 
 
Study Anti-oxidant  
Parameters 
Robust Pre-frail Frail 
Ble (20) Plasma vitamin 
E µmol/L 
26.7  28.6  29.6* 
Goulet  (22) vitamin C (µmol 
L-1) 
36.4 ± 20.5 
(robust+pre-frail) 
NA 43.8 ± 28.8 
 
α-Tocopherol 
(µmol L-1) 
17.8 ± 13.4 
(robust+pre-frail) 
NA FL: 20.2 ± 16.9 
FO: 20.8 ± 16.6 
Saum (14) BAP ( μmol/L) 2,567.0~ 
(2,454.6 – 
2,684.3) 
2,573.8~ 
(2,448.9 – 2698.9) 
2,609.7~ 
(2,449.3 – 
2,728.8) 
TTL ( µmol/L) 342.1~ 
(294.0 – 386.9) 
327.6~ 
(277.2 – 377.9) 
302.9~ ** 
(255.8 – 355.5) 
Namioka, 2016 
(25) 
BAP(μmol/L) 2,599± 627 2,501±586 2,390± 680 * 
